Previous 10 | Next 10 |
BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022. The webcast and conference call will be ...
Urovant Sciences and French pharmaceutical company Pierre Fabre Médicament have entered into a licensing agreement to commercialize oral treatment vibegron for overactive bladder (OAB) in the European Economic Area, UK and Switzerland. Urovant is a unit of Sumitovant Bio...
CAMBRIDGE, Mass. and BASEL, Switzerland, June 27, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today it is among the National Organization for Rare Disorders (NORD) 2022 Industry Innovation Aw...
BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol ...
Better Therapeutics (NASDAQ:BTTX) stated Tuesday that Frank Karbe has been appointed as company's new President and CEO, effective July 5, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. Frank joins in from Myova...
BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chie...
BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE ® ...
Spirovant Launches State-of-the-Art Laboratory and Headquarters PR Newswire The facilities are located in the center of Philadelphia's thriving life sciences corridor PHILADELPHIA , May 16, 2022 /PRNewswire/ -- Spirovant Sciences , a gene ...
Do You Have These Top Biotech Stocks On Your Watchlist? Depending on your investment appetite, the stock market offers various types of opportunities. Biotech stocks have a reputation for being a high-risk, high-reward sector to invest in. This is an industry that includes compa...
Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q4 2021 Earnings Call May 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q4 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...